{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:19:02Z","timestamp":1762352342312},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,8,7]],"date-time":"2014-08-07T00:00:00Z","timestamp":1407369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s11060-014-1533-z","type":"journal-article","created":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T15:08:10Z","timestamp":1407337690000},"page":"147-154","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib"],"prefix":"10.1007","volume":"120","author":[{"given":"L.","family":"Peuvrel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Saint-Jean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Qu\u00e9reux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Brocard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Khammari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. C.","family":"Knol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Dr\u00e9no","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,7]]},"reference":[{"issue":"14","key":"1533_CR1","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","volume":"22","author":"JS Barnholtz-Sloan","year":"2004","unstructured":"Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22(14):2865\u20132872","journal-title":"J Clin Oncol"},{"issue":"10","key":"1533_CR2","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1586\/ern.12.111","volume":"12","author":"E Fonkem","year":"2012","unstructured":"Fonkem E, Uhlmann EJ, Floyd SR, Mahadevan A, Kasper E, Eton O, Wong ET (2012) Melanoma brain metastases: overview of current management and emerging targeted therapies. Expert Rev Neurother 12(10):1207\u20131215","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"1533_CR3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00401-011-0933-9","volume":"123","author":"M Preusser","year":"2012","unstructured":"Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R, Marosi C, Zielinski C, Mehta MP, Winkler F, Wick W, von Deimling A (2012) Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 123(2):205\u2013222","journal-title":"Acta Neuropathol"},{"issue":"8","key":"1533_CR4","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","volume":"117","author":"MA Davies","year":"2011","unstructured":"Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, Bedikian A (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117(8):1687\u20131696","journal-title":"Cancer"},{"key":"1533_CR5","first-page":"391","volume":"6","author":"AM Menzies","year":"2012","unstructured":"Menzies AM, Long GV, Murali R (2012) Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther 6:391\u2013405","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"1533_CR6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ctrv.2013.06.004","volume":"39","author":"J Murrell","year":"2013","unstructured":"Murrell J, Board R (2013) The use of systemic therapies for the treatment of brain metastases in metastatic melanoma: Opportunities and unanswered questions. Cancer Treat Rev 39(8):833\u2013838","journal-title":"Cancer Treat Rev"},{"key":"1533_CR7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1200\/EdBook_AM.2013.33.393","volume":"2013","author":"GV Long","year":"2013","unstructured":"Long GV, Margolin KA (2013) Multidisciplinary approach to brain metastases from melanoma. Am Soc Clin Oncol Educ Book 2013:393\u2013398","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"15","key":"1533_CR8","first-page":"1628","volume":"29","author":"KB Kim","year":"2011","unstructured":"Kim KB, Flaherty KT, Chapman PB, Sosman JA, Ribas A, McArthur GA, Amaravadi RK, Lee RJ, Nolop KB, Puzanov I (2011) Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM). J Clin Oncol 29(15):1628\u20131634","journal-title":"J Clin Oncol"},{"issue":"11","key":"1533_CR9","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1200\/JCO.2012.45.2870","volume":"31","author":"A Maleka","year":"2013","unstructured":"Maleka A, Enblad G, Sjors G, Lindqvist A, Ullenhag GJ (2013) Treatment of metastatic malignant melanoma with vemurafenib during pregnancy. J Clin Oncol 31(11):e192\u2013e193","journal-title":"J Clin Oncol"},{"issue":"10","key":"1533_CR10","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.mayocp.2012.07.006","volume":"87","author":"NM Rochet","year":"2012","unstructured":"Rochet NM, Dronca RS, Kottschade LA, Chavan RN, Gorman B, Gilbertson JR, Markovic SN (2012) Melanoma brain metastases and vemurafenib: need for further investigation. Mayo Clin Proc 87(10):976\u2013981","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"1533_CR11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1752-1947-6-131","volume":"6","author":"E Simeone","year":"2012","unstructured":"Simeone E, De Maio E, Sandomenico F, Fulciniti F, Lastoria S, Aprea P, Staibano S, Montesarchio V, Palmieri G, Mozzillo N, Ascierto PA (2012) Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report. J Med Case Rep 6(1):131","journal-title":"J Med Case Rep"},{"issue":"2","key":"1533_CR12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/CMR.0b013e32835e589c","volume":"23","author":"JM Lee","year":"2013","unstructured":"Lee JM, Mehta UN, Dsouza LH, Guadagnolo BA, Sanders DL, Kim KB (2013) Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report. Melanoma Res 23(2):175\u2013178","journal-title":"Melanoma Res"},{"issue":"7377","key":"1533_CR13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","volume":"480","author":"PI Poulikakos","year":"2011","unstructured":"Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480(7377):387\u2013390","journal-title":"Nature"},{"key":"1533_CR14","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/ncomms1727","volume":"3","author":"H Shi","year":"2012","unstructured":"Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS (2012) Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3:724","journal-title":"Nat Commun"},{"issue":"12","key":"1533_CR15","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1158\/0008-5472.CAN-07-6787","volume":"68","author":"C Montagut","year":"2008","unstructured":"Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J (2008) Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 68(12):4853\u20134861","journal-title":"Cancer Res"},{"issue":"22","key":"1533_CR16","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","volume":"29","author":"N Wagle","year":"2011","unstructured":"Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29(22):3085\u20133096","journal-title":"J Clin Oncol"},{"issue":"7326","key":"1533_CR17","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","volume":"468","author":"CM Johannessen","year":"2010","unstructured":"Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468(7326):968\u2013972","journal-title":"Nature"},{"issue":"6","key":"1533_CR18","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","volume":"18","author":"J Villanueva","year":"2010","unstructured":"Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D\u2019Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3\u00a0K. Cancer Cell 18(6):683\u2013695","journal-title":"Cancer Cell"},{"issue":"9","key":"1533_CR19","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMe1005370","volume":"363","author":"KS Smalley","year":"2010","unstructured":"Smalley KS, Sondak VK (2010) Melanoma\u2013an unlikely poster child for personalized cancer therapy. Engl J Med 363(9):876\u2013878","journal-title":"Engl J Med"},{"issue":"7326","key":"1533_CR20","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","volume":"468","author":"R Nazarian","year":"2010","unstructured":"Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468(7326):973\u2013977","journal-title":"Nature"},{"issue":"1","key":"1533_CR21","first-page":"76","volume":"2","author":"F Meier","year":"2013","unstructured":"Meier F, Forschner A, Klumpp B, Flaherty KT, Honegger JB, Witte M, Bornemann A, Dummer R, Bauer J, Tabatabai G, Weide B, Eigentler TK, Schadendorf D, Quintanilla-Fend L, Niessner H, Garbe C (2013) Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases Cancer Med 2(1):76\u201385","journal-title":"Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases Cancer Med"},{"issue":"3","key":"1533_CR22","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/jpet.112.201475","volume":"344","author":"RK Mittapalli","year":"2013","unstructured":"Mittapalli RK, Vaidhyanathan S, Dudek AZ, Elmquist WF (2013) Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther 344(3):655\u2013664","journal-title":"J Pharmacol Exp Ther"},{"issue":"9829","key":"1533_CR23","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","volume":"379","author":"GS Falchook","year":"2012","unstructured":"Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O\u2019Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379(9829):1893\u20131901","journal-title":"Lancet"},{"issue":"3","key":"1533_CR24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2174\/156800912799277511","volume":"12","author":"D Fortin","year":"2012","unstructured":"Fortin D (2012) The blood-brain barrier: its influence in the treatment of brain tumors metastases. Curr Cancer Drug Targets 12(3):247\u2013259","journal-title":"Curr Cancer Drug Targets"},{"issue":"3","key":"1533_CR25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11060-013-1127-1","volume":"113","author":"A Narayana","year":"2013","unstructured":"Narayana A, Mathew M, Tam M, Kannan R, Madden KM, Golfinos JG, Parker EC, Ott PA, Pavlick AC (2013) Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 113(3):411\u2013416","journal-title":"J Neurooncol"},{"issue":"1","key":"1533_CR26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/jpet.112.192195","volume":"342","author":"RK Mittapalli","year":"2012","unstructured":"Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF (2012) Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther 342(1):33\u201340","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"1533_CR27","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1021\/mp3003144","volume":"9","author":"S Durmus","year":"2012","unstructured":"Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH (2012) Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Mol Pharm 9(11):3236\u20133245","journal-title":"Mol Pharm"},{"key":"1533_CR28","doi-asserted-by":"crossref","first-page":"9060","DOI":"10.1200\/jco.2013.31.15_suppl.9060","volume":"31","author":"JJ Harding","year":"2013","unstructured":"Harding JJ, Catalanotti F, Yaqubie A, McDermott GC, Kersellius R, Merghoub T (2013) Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets). J Clin Oncol 31:9060","journal-title":"J Clin Oncol"},{"key":"1533_CR29","doi-asserted-by":"crossref","unstructured":"Dzienis MR, Atkinson VG (2014).Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases. Melanoma Res 24(4):349\u2013353","DOI":"10.1097\/CMR.0000000000000068"},{"issue":"3","key":"1533_CR30","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejca.2013.11.002","volume":"50","author":"R Dummer","year":"2014","unstructured":"Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, Veronese L, Hilfiker PR, Felderer L, Rinderknecht JD (2014) Vemurafenib in patients with BRAF mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 50(3):611\u2013621","journal-title":"Eur J Cancer"},{"issue":"2","key":"1533_CR31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1684\/ejd.2014.2300","volume":"24","author":"B Baroudjian","year":"2014","unstructured":"Baroudjian B, Boussemart L, Routier E, Dreno B, Tao Y, Deutsch E, Blanchard P, Dhermain F, Vilcot L, Vagner S, Eggermont A, Mateus C, Robert C (2014) Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer? Eur J Dermatol 24(2):265\u2013267","journal-title":"Eur J Dermatol"},{"issue":"6","key":"1533_CR32","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1684\/ejd.2013.2193","volume":"23","author":"L Peuvrel","year":"2013","unstructured":"Peuvrel L, Ruellan AL, Thillays F, Quereux G, Brocard A, Saint-Jean M, Aumont M, Drouet F, Dreno B (2013) Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. Eur J Dermatol 23(6):879\u2013881","journal-title":"Eur J Dermatol"},{"issue":"11","key":"1533_CR33","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","volume":"13","author":"GV Long","year":"2012","unstructured":"Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13(11):1087\u20131095","journal-title":"Lancet Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-014-1533-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-014-1533-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-014-1533-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T23:46:46Z","timestamp":1598140006000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-014-1533-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,7]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["1533"],"URL":"https:\/\/doi.org\/10.1007\/s11060-014-1533-z","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,7]]}}}